Dr. Peter Reiss: Moving Towards the Fourth “90” Goal – Strategies for Improving the Quality of Life and Management of HIV/AIDS Patients

Dr. Peter Reiss: Moving Towards the Fourth “90” Goal – Strategies for Improving the Quality of Life and Management of HIV/AIDS Patients

2024.02.19
Honorary Dr. at the Amsterdam University Medical Center, University of Amsterdam, former President of the European AIDS Clinical Society (EACS) (2008-2012), former Regional Director for Europe and Central Asia on the Governing Council of the International AIDS Society (IAS) (2006-2014), Co-Chair of the 22nd International AIDS Conference (AIDS 2018), Director of the Netherlands HIV Monitoring Foundation, member of the National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NAID) HIV Vaccine Data and Safety Monitoring Board, and member of various committees including CROI, EACS, and HIV Glasgow.
IAS 2023 | RESPOND Study: INSTIs Might Indeed be “A Bit Sweet”

IAS 2023 | RESPOND Study: INSTIs Might Indeed be “A Bit Sweet”

2024.01.14
Integrase strand transfer inhibitors (INSTIs) are associated with weight gain, but this weight gain doesn't harm survival or increase cardiovascular disease (CVD) risk. So, does the weight gain associated with INSTIs lead to a higher risk of diabetes? At the recent 12th International AIDS Society (IAS) HIV Science Conference (IAS 2023), the renowned RESPOND cohort study from Europe and America indicated that INSTIs might increase the risk of diabetes onset. Even after adjustment, the onset risk remains statistically significant.
Dr. Hongzhou Lu: NAD Management is Key for HIV Patients, Not Just Changing Medication

Dr. Hongzhou Lu: NAD Management is Key for HIV Patients, Not Just Changing Medication

2024.01.14
The use of highly active antiretroviral therapy (HAART) has led to effective virological control in HIV-infected individuals, significantly reducing mortality rates and transforming AIDS into a treatable and manageable chronic disease. Today, one of the main clinical challenges is how to choose more "efficient and less toxic" treatment options to improve patients' quality of life. At the 12th International AIDS Society HIV Science Conference (IAS 2023) held recently, the first randomized controlled trial on switching to integrase strand transfer inhibitor (INSTI)-based therapy to control weight gain was reported. Infectious Disease Frontier invited Dr. Hongzhou Lu from Shenzhen Third People's Hospital, China, to interpret this trial and share insights into the current and future management of non-AIDS defining diseases (NAD) in HIV-infected individuals.

Integrase Inhibitors Do Not Increase Cardiovascular Event Risk in HIV Patients

2023.12.08
This article discusses a significant study presented at the 19th European AIDS Conference (EACS 2023), held in Warsaw, Poland, from October 18-20, 2023. Professor Bernard Surial from the University of Bern in Switzerland shared the results of an international cohort study, which revealed that the use of integrase strand transfer inhibitors (INSTIs) in the treatment of HIV does not increase the risk of cardiovascular events.
Dr. Peter Reiss: Moving Towards the Fourth “90” Goal – Strategies for Improving the Quality of Life and Management of HIV/AIDS Patients

Dr. Peter Reiss: Moving Towards the Fourth “90” Goal – Strategies for Improving the Quality of Life and Management of HIV/AIDS Patients

2023.10.22
Honorary Dr. at the Amsterdam University Medical Center, University of Amsterdam, former President of the European AIDS Clinical Society (EACS) (2008-2012), former Regional Director for Europe and Central Asia on the Governing Council of the International AIDS Society (IAS) (2006-2014), Co-Chair of the 22nd International AIDS Conference (AIDS 2018), Director of the Netherlands HIV Monitoring Foundation, member of the National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NAID) HIV Vaccine Data and Safety Monitoring Board, and member of various committees including CROI, EACS, and HIV Glasgow.
IAS 2023 | RESPOND Study: INSTIs Might Indeed be “A Bit Sweet”

IAS 2023 | RESPOND Study: INSTIs Might Indeed be “A Bit Sweet”

2023.10.22
Integrase strand transfer inhibitors (INSTIs) are associated with weight gain, but this weight gain doesn't harm survival or increase cardiovascular disease (CVD) risk. So, does the weight gain associated with INSTIs lead to a higher risk of diabetes? At the recent 12th International AIDS Society (IAS) HIV Science Conference (IAS 2023), the renowned RESPOND cohort study from Europe and America indicated that INSTIs might increase the risk of diabetes onset. Even after adjustment, the onset risk remains statistically significant.
Dr.HongzhouLu: NAD Management is Key for HIV Patients, Not Just Changing Medication

Dr.HongzhouLu: NAD Management is Key for HIV Patients, Not Just Changing Medication

2023.10.12
The use of highly active antiretroviral therapy (HAART) has led to effective virological control in HIV-infected individuals, significantly reducing mortality rates and transforming AIDS into a treatable and manageable chronic disease. Today, one of the main clinical challenges is how to choose more "efficient and less toxic" treatment options to improve patients' quality of life. At the 12th International AIDS Society HIV Science Conference (IAS 2023) held recently, the first randomized controlled trial on switching to integrase strand transfer inhibitor (INSTI)-based therapy to control weight gain was reported. Infectious Disease Frontier invited Dr. Hongzhou Lu from Shenzhen Third People's Hospital, China, to interpret this trial and share insights into the current and future management of non-AIDS defining diseases (NAD) in HIV-infected individuals.